Instead of ensuring that Americans get lifechanging new products, misusing march-in rights would ensure that taxpayer-funded research discoveries never make it out of the lab.
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services.
RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people are talking about.
Politico recently reported that RFK Jr. has “expressed openness” to seizing drug companies’ patents and relicensing them to generic manufacturers—a move that would effectively implement roundabout price controls on some of the nation’s most commonly prescribed drugs.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
RFK Jr.’s Confirmation Hearings Can’t Leave This Question Unanswered
Sally C. Pipes
Instead of ensuring that Americans get lifechanging new products, misusing march-in rights would ensure that taxpayer-funded research discoveries never make it out of the lab.
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services.
RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people are talking about.
Politico recently reported that RFK Jr. has “expressed openness” to seizing drug companies’ patents and relicensing them to generic manufacturers—a move that would effectively implement roundabout price controls on some of the nation’s most commonly prescribed drugs.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.